These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 23645247)

  • 1. Building a new biomedical ecosystem: Pfizer's Centers for Therapeutic Innovation.
    Patel AC; Coyle AJ
    Clin Pharmacol Ther; 2013 Sep; 94(3):314-6. PubMed ID: 23645247
    [No Abstract]   [Full Text] [Related]  

  • 2. Improving the efficacy of translational medicine by optimally integrating health care, academia and industry.
    Bornstein SR; Licinio J
    Nat Med; 2011 Dec; 17(12):1567-9. PubMed ID: 22146467
    [No Abstract]   [Full Text] [Related]  

  • 3. Academia-pharma partnerships for novel drug discovery: essential or nice to have?
    Palmer M; Chaguturu R
    Expert Opin Drug Discov; 2017 Jun; 12(6):537-540. PubMed ID: 28394189
    [No Abstract]   [Full Text] [Related]  

  • 4. Europe's innovation hub finally KICs off.
    Gilbert N
    Nature; 2011 Feb; 470(7335):450. PubMed ID: 21350459
    [No Abstract]   [Full Text] [Related]  

  • 5. Pfizer's home remedy.
    Abkowitz A
    Fortune; 2009 Aug; 160(4):82-4, 86. PubMed ID: 19728588
    [No Abstract]   [Full Text] [Related]  

  • 6. Open PHACTS: semantic interoperability for drug discovery.
    Williams AJ; Harland L; Groth P; Pettifer S; Chichester C; Willighagen EL; Evelo CT; Blomberg N; Ecker G; Goble C; Mons B
    Drug Discov Today; 2012 Nov; 17(21-22):1188-98. PubMed ID: 22683805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational research and the evolving landscape for biomedical innovation.
    Kaitin KI
    J Investig Med; 2012 Oct; 60(7):995-8. PubMed ID: 22918200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Address from the previous President, January 17, 2013].
    Léger JM
    Rev Neurol (Paris); 2013 Mar; 169(3):214-5. PubMed ID: 23453275
    [No Abstract]   [Full Text] [Related]  

  • 9. An audience with...Francis Collins. Interviewed by Asher Mullard.
    Collins F
    Nat Rev Drug Discov; 2011 Jan; 10(1):14. PubMed ID: 21151031
    [No Abstract]   [Full Text] [Related]  

  • 10. The innovative medicines initiative: a European response to the innovation challenge.
    Goldman M
    Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcry over plans for 'Japanese NIH'.
    Fuyuno I
    Nature; 2013 Jul; 499(7457):136-7. PubMed ID: 23846639
    [No Abstract]   [Full Text] [Related]  

  • 12. Improving R&D productivity of pharmaceutical companies through public-private partnership: experiences from the Innovative Medicines Initiative.
    Laverty H; Gunn M; Goldman M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):545-8. PubMed ID: 23136843
    [No Abstract]   [Full Text] [Related]  

  • 13. Playing well with others! Initiating and sustaining successful collaborations between industry, academia and government.
    Thomas CJ; McKew JC
    Curr Top Med Chem; 2014; 14(3):291-3. PubMed ID: 24283974
    [No Abstract]   [Full Text] [Related]  

  • 14. Intellectual property policies in early-phase research in public-private partnerships.
    Stevens H; Van Overwalle G; Van Looy B; Huys I
    Nat Biotechnol; 2016 May; 34(5):504-10. PubMed ID: 27153280
    [No Abstract]   [Full Text] [Related]  

  • 15. Anecdotes from ITMAT: building capacity for translational science.
    FitzGerald GA
    Clin Pharmacol Ther; 2013 Sep; 94(3):291-6. PubMed ID: 23963214
    [No Abstract]   [Full Text] [Related]  

  • 16. Building a life sciences innovation ecosystem.
    Harrison KD; Kadaba NS; Kelly RB; Crawford D
    Sci Transl Med; 2012 Oct; 4(157):157fs37. PubMed ID: 23100622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global health needs to fill the innovation gap.
    Mundel T
    Nat Med; 2012 Dec; 18(12):1735. PubMed ID: 23223055
    [No Abstract]   [Full Text] [Related]  

  • 18. Allocation of control rights and cooperation efficiency in public-private partnerships: theory and evidence from the Chinese pharmaceutical industry.
    Zhang Z; Jia M; Wan D
    Int J Health Care Finance Econ; 2009 Jun; 9(2):169-82. PubMed ID: 19360467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Funding bodies should foster partnerships between industry and academia.
    Tzircotis G; Hickson T; Foulkes I
    Nat Rev Cancer; 2021 Feb; 21(2):65-66. PubMed ID: 33398101
    [No Abstract]   [Full Text] [Related]  

  • 20. Indian biotechs partner with government.
    Jayaraman KS
    Nat Biotechnol; 2009 Apr; 27(4):305. PubMed ID: 19352355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.